Regenxbio’s Second Clinical Hold in Eight Months Exposes a Safety Monitoring System That Was Never Rebuilt After the First One
FDA hits RGX-121 with a second clinical hold in 2026 over spine MRI findings in 5 patients—revealing systemic monitoring...
